Power Law company profile

AxoGen

Biotech & Life Sciences · Alachua, United States · Founded 2002 · IPO 2003 Thoroughbred

Developing technologies for peripheral nerve regeneration and repair

Valuation

$2.22B

Market cap · May/2026

Revenue

$225M

Latest reported FY

EBITDA

$34M

Latest reported FY

Featured in $10B+ revenueThoroughbred · Power Law outcome

Investors

1 investor on AxoGen's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series B+ 1 investor entered at this stage

Emory University

Global footprint

Where AxoGen has talent and traffic

Workforce by country

3 countries with
team presence

🇺🇸 United States99.3%

🇩🇪 Germany0.5%

🇨🇦 Canada0.2%

3 countries shown

Web traffic by country

2.9K monthly visits
across markets

🇺🇸 United States86.2%

Top 1 markets shown

Market sentiment

What the market is saying about AxoGen

An AI-synthesized read of the highest-engagement posts about AxoGen on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See AxoGen on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles